On Tuesday, the National Institutes of Health (NIH) declared the commencement of two noteworthy clinical trials that are intended to assess the efficacy and safety of an HIV pre-exposure prophylaxis (PrEP) medication among marginalized demographic groups. This effort, which focuses on groups like women and intravenous drug users that have previously been underrepresented in clinical...
